Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

0.9299 -0.0201 (-2.12%)
Streaming Delayed Price Updated: 10:40 AM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Via ACCESS Newswire
News headline image
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Via ACCESS Newswire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Via ACCESS Newswire
News headline image
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Via ACCESS Newswire
News headline image
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Via ACCESS Newswire
News headline image
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Via ACCESS Newswire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
From Revelation Biosciences Inc.
Via Business Wire
News headline image
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
From Revelation Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.